alpha-Lipoic acid treatment decreases serum lactate and pyruvate concentrations and improves glucose effectiveness in lean and obese patients with type 2 diabetes

Author(s): Konrad T, Vicini P, Kusterer K, Höflich A, Assadkhani A, et al.


Objective: We examined the effect of lipoic acid (LA), a cofactor of the pyruvate dehydrogenase complex (PDH), on insulin sensitivity (SI) and glucose effectiveness (SG) and on serum lactate and pyruvate levels after oral glucose tolerance tests (OGTTs) and modified frequently sampled intravenous glucose tolerance tests (FSIGTTs) in lean (n = 10) and obese (n = 10) patients with type 2 diabetes.

Research design and methods: FSIGTT data were analyzed by minimal modeling technique to determine SI and SG before and after oral treatment (600 mg, twice a day, for 4 weeks). Serum lactate and pyruvate levels of diabetic patients after glucose loading were compared with those of lean (n = 10) and obese (n = 10) healthy control subjects in which SI and SG were also determined from FSIGTT data.

Results: Fasting lactate and pyruvate levels were significantly increased in patients with type 2 diabetes. These metabolites did not exceed elevated fasting concentrations after glucose loading in lean patients with type 2 diabetes. However, a twofold increase of lactate and pyruvate levels was measured in obese diabetic patients. LA treatment was associated with increased SG in both diabetic groups (lean 1.28 +/- 0.14 to 1.93 +/- 0.13; obese 1.07 +/- 0.11 to 1.53 +/- 0.08 x 10(-2) min-1, P < 0.05). Higher SI and lower fasting glucose were measured in lean diabetic patients only (P < 0.05). Lactate and pyruvate before and after glucose loading were approximately 45% lower in lean and obese diabetic patients after LA treatment.

Conclusions: Treatment of lean and obese diabetic patients with LA prevents hyperglycemia-induced increments of serum lactate and pyruvate levels and increases SG.

Similar Articles

Mitochondrial dysfunction in obesity

Author(s): Bournat JC, Brown CW

Increased oxidative stress in obesity and its impact on metabolic syndrome

Author(s): Furukawa S, Fujita T, Shimabukuro M, Iwaki M, Yamada Y, et al.

Lipoic acid as a potential therapy for chronic diseases associated with oxidative stress

Author(s): Smith AR, Shenvi SV, Widlansky M, Suh JH, Hagen TM

Lipoic acid reduces glycemia and increases muscle GLUT4 content in streptozotocin-diabetic rats

Author(s): Khamaisi M, Potashnik R, Tirosh A, Demshchak E, Rudich A, et al.

Lipoic acid prevents body weight gain induced by a high fat diet in rats: effects on intestinal sugar transport

Author(s): Prieto-Hontoria PL, Pérez-Matute P, Fernández-Galilea M, Barber A, Martínez JA, et al.

Anti-obesity effect of SR141716, a CB1 receptor antagonist, in diet-induced obese mice

Author(s): Ravinet Trillou C, Arnone M, Delgorge C, Gonalons N, Keane P, et al.

Effects of oxidative stress on adiponectin secretion and lactate production in 3T3-L1 adipocytes

Author(s): Soares AF, Guichardant M, Cozzone D, Bernoud-Hubac N, Bouzaïdi-Tiali N

Hypothalamic CB1 Cannabinoid Receptors Regulate Energy Balance in Mice

Author(s): Cardinal P, Bellocchio L, Clark S, Cannich A, Klugmann M, et al.

Serotonin 2C receptor agonists improve type 2 diabetes via melanocortin-4 receptor signaling pathways

Author(s): Zhou L, Sutton GM, Rochford JJ, Semple RK, Lam DD, et al.

A mouse model for the metabolic effects of the human fat mass and obesity associated FTO gene

Author(s): Church C, Lee S, Bagg EA, McTaggart JS, Deacon R, et al.

Dysfunction of mitochondria in human skeletal muscle in type 2 diabetes

Author(s): Kelley DE, He J, Menshikova EV, Ritov VB

Oxidative capacity and aging in human muscle

Author(s): Conley KE, Jubrias SA, Esselman PC

Mitochondrial function and apoptotic susceptibility in aging skeletal muscle

Author(s): Chabi B, Ljubicic V, Menzies KJ, Huang JH, Saleem A, et al.

Excessive loss of skeletal muscle mass in older adults with type 2 diabetes

Author(s): Park SW, Goodpaster BH, Lee JS, Kuller LH, Boudreau R, et al.